Related Experiment Videos
Amlodipine in hypertension: its effects on platelet aggregation and dynamic exercise
R Hernández1, A R Carvajal, M J Armas-de Hernande
1Clinical Pharmacology Unit, School of Medicine, Centro Occidental, Lisandro Alvarado University, Barquisimeto, Venezuela.
Journal of Cardiovascular Pharmacology
|January 1, 1991
Summary
Once-daily amlodipine effectively lowers blood pressure in patients with essential hypertension. This medication also significantly reduces platelet aggregation, indicating a dual therapeutic benefit.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Essential hypertension is a prevalent cardiovascular condition.
- Amlodipine is a calcium channel blocker used for hypertension.
Purpose of the Study:
- To evaluate the antihypertensive efficacy and safety of once-daily amlodipine (5-10 mg).
- To assess the effects of amlodipine on platelet aggregation.
Main Methods:
- Open-label chronic study with a placebo run-in period.
- Patients received amlodipine (mean 7 mg/day) for 12 weeks.
- Acute single 10-mg dose assessed for effects on exercise response and platelet aggregation.
Main Results:
- Amlodipine significantly reduced supine, sitting, standing, and postexercise blood pressures (p < 0.005).
- No significant changes in heart rate were observed.
- A single 10-mg dose reduced blood pressure without altering exercise response.
- Amlodipine significantly inhibited collagen- and ADP-induced platelet aggregation (p < 0.005).
Conclusions:
- Once-daily amlodipine is an effective antihypertensive agent.
- Amlodipine demonstrates a significant inhibitory effect on platelet aggregation.